Celldex Therapeutics (CLDX) Capital Expenditures (2010 - 2026)
Celldex Therapeutics (CLDX) posted quarterly Capital Expenditures of $1.6 million for Q1 2026, up 518.49% year-over-year from $265000.0 in Q1 2025, and up 27.95% quarter-over-quarter from $1.3 million in Q4 2025.
Celldex Therapeutics (CLDX) Capital Expenditures (2010 - 2026) Analysis & Trends
Celldex Therapeutics' Capital Expenditures history runs 17 years deep, the most recent figure standing at $1.6 million for Q1 2026.
- In Q1 2026, Capital Expenditures rose 518.49% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at $4.1 million (up 122.17% YoY), while the FY2025 annual figure was $2.7 million, up 41.43% from the prior year.
- Capital Expenditures for Q1 2026 stood at $1.6 million, up from $1.3 million in the prior quarter.
- The five-year high for Capital Expenditures was $1.6 million in Q1 2026, with the low at $157000.0 in Q3 2023.
- The 5-year median for Capital Expenditures is $545000.0 (2024), against an average of $583411.8.
- The sharpest annual moves came in 2023 and 2026: Capital Expenditures tumbled 54.49% in 2023, then surged 518.49% in 2026.
- Celldex Therapeutics' Capital Expenditures stood at $235000.0 in 2022, then jumped by 183.4% to $666000.0 in 2023, then advanced by 13.51% to $756000.0 in 2024, then soared by 69.44% to $1.3 million in 2025, then advanced by 27.95% to $1.6 million in 2026.
- Business Quant data shows CLDX's Capital Expenditures at $1.6 million in Q1 2026, $1.3 million in Q4 2025, and $440000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Celldex Therapeutics | 3.29 Bn | 2.58 Bn | -2.57 Mn | 3.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.18 Mn |
| Jun 30, 2026 | 3.18 Mn |
| Mar 31, 2026 | 1.64 Mn |
| Mar 31, 2026 | 1.64 Mn |
| Dec 31, 2025 | 1.28 Mn |
| Dec 31, 2025 | 1.28 Mn |
| Sep 30, 2025 | 440,000.00 |
| Sep 30, 2025 | 440,000.00 |
| Jun 30, 2025 | 728,000.00 |
| Jun 30, 2025 | 728,000.00 |
| Mar 31, 2025 | 265,000.00 |
| Mar 31, 2025 | 265,000.00 |
| Dec 31, 2024 | 756,000.00 |
| Dec 31, 2024 | 756,000.00 |
| Sep 30, 2024 | 545,000.00 |
| Sep 30, 2024 | 545,000.00 |
| Jun 30, 2024 | 274,000.00 |
| Jun 30, 2024 | 274,000.00 |
| Mar 31, 2024 | 344,000.00 |
| Mar 31, 2024 | 344,000.00 |